TriSalus Life Sciences Inc, popularly known as TLSI, is a pioneering medical and pharmaceutical company focused on the development and commercialization of groundbreaking technologies to manage solid tumors’ drug delivery. Its mission lies centrally in the advancement of effective treatment methodologies for patients suffering from hard-to-treat cancers like pancreatic, liver, and other solid tumor cancers.
As a healthcare company that stands at the forefront of innovation, TLSI digs into the power of its proprietary FDA-EUA-cleared technology, namely Pressure Enabled Drug Delivery (PEDD™), with SmartValve® technology, which has shown promising results in overcoming the limitations that standard chemo-administration encounters. It is believed that this advanced technology helps increase the drug absorption by the tumors, maximizing the effectiveness of oncology treatments.
Another prominent aspect of TLSI is its dedication to research and clinical investigations. The company conducts comprehensive clinical studies in collaboration with leading healthcare professionals and institutions. These studies are aimed towards exploring the potentials of PEDD technology in several interventions, including both first-line and salvage therapies. Through extensive research & development and clinical collaborations, TriSalus Life Sciences is committed to providing advanced treatment alternatives and setting new standards in cancer care.
Based in Westminster, Colorado, the company has a dynamic and qualified team of healthcare professionals, engineers, and clinicians who share the company's passion for transforming the lives of patients through its innovative health solutions. Besides, TLSI also maintains an unwavering commitment to safety, compliance, and clinical excellence, ensuring that it delivers the most effective, reliable, and safe solutions for cancer patients worldwide.
TriSalus Life Sciences Inc. is much more than just a pharmaceutical company; it combines science and technology to improve patient lives and change the way we think about cancer treatments. As the epitome of breakthrough medical technology, TLSI holds a significant position in the innovative field of oncology. Through continuous innovation and commitment, the company aims to make a substantial difference in the global health care sector, especially in drastically improving the quality of life for those battling cancer. With its focus strongly pivot around “life,” TriSalus Life Sciences Inc. continues to fuel its journey towards a healthier future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
TriSalus Life Sciences reported strong Q2 2026 revenue of $11.4 million, showing sequential and year-over-year growth, primarily driven by their TRINAV system and an expanded commercial team. Key developments include a new CMS G code allowing TRINAV reimbursement in office-based labs (OBLs), and ongoing clinical trials to validate their pressure-enabled drug delivery (PEDD) technology across various indications. The company reiterated its full-year 2026 revenue guidance of $54 million to $57 million, anticipating continued growth and improved productivity from its sales force in the latter half of the year.
TriSalus Life Sciences received FDA 510(k) clearance for its TriNav Advance, an expansion of its pressure-enabled drug delivery platform for interventional oncology. Despite the positive news, the company's stock (TLSI) is testing key support levels around $5.89, with critical resistance at $6.00 and support at $4.50. The Benzinga Edge scorecard highlights a bullish momentum signal for TLSI, suggesting that trend followers should monitor its ability to hold key breakout levels.
The FDA has granted 510(k) clearance to TriSalus Life Sciences for its TriNav Advance device, designed to enhance tumor penetration during liver embolization procedures. This catheter-based system extends the company's Pressure-Enabled Drug Delivery (PEDD) technology to smaller hepatic vessels, utilizing a SmartValve mechanism to improve drug and microsphere delivery to tumors while minimizing exposure to healthy tissue. Preclinical studies have supported the effectiveness of PEDD in increasing therapeutic concentration within tumors.
TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15.6% in pre-market trading after receiving 510(k) clearance from the FDA for its TriNav Advance device. This new device is designed to enhance pressure-enabled drug delivery in liver embolization procedures, particularly for smaller, distal vessels. TriSalus plans a limited market release in the coming weeks and previously raised its full-year 2026 revenue guidance.